Pacira BioSciences 株価情報 (NASDAQ: PCRX)

最新ニュース Pacira BioSciences (NASDAQ:PCRX) 株価情報

Pacira BioSciences

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Pacira BioSciences Inc

U.S. stocks were lower, with the Dow Jones index falling over 700 points on Friday.
Shares of TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose sharply in today's session after the company reported <a href="https://www.benzinga.com/25/01/42915528/td-synnex-shares-delivers-earnings-beat-and-boosts-dividend-by-10">better-than-expected quarterly financial results.</a>
Quarterly revenue of $15.85 billion, up 10% Y/Y, exceeded the analyst view of $15.22 billion. The Fremont, California-based company reported an adjusted EPS of $3.09, beating the street view of $3.05.
TD Synnex shares jumped 5.5% to $128.76 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares jumped 37.3% to $2.57 after the company announced a developments in its True All-Solid-State Battery technology.</li>
<li>Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) gained 23.6% to $11.40 after the company reported better-than-expected first-quarter financial results.</li>
<li>Savers Value Village Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) surged 13.5% to $10.63 after the company reported preliminary fourth quarter and full year net sales.</li>
<li>Oculis Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) gained 13.1% to $21.14.</li>
<li>Sasol Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) gained 13.1% to $4.99.</li>
<li>Pacira Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) climbed 12.1% to $20.83 after the company reported a preliminary year-over-year increase in FY25 revenue.</li>
<li>Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) gained 10.6% to $28.97 after the company announced it increased its quarterly dividend.</li>
<li>Merus NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) gained 9.8% to $46.35.</li>
<li>Teekay Tankers Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNK#NYSE">TNK</a>) rose 8.1% to $45.56.</li>
<li>Talos Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) gained 6.2% to $10.58.</li>
<li>TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose 5.5% to $128.76 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42912948/top-3-materials-stocks-that-are-set-to-fly-this-month">Top 3 Materials Stocks That Are Set To Fly This Month</a></li>
</ul>

News

Intraday Update

Markets

Movers

Trading Ideas

MRUS

MVST

PCRX

RPRX

TALO

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday

WIIM

Pacira Biosciences shares are trading higher after the company reported a preliminary year-over-year increase in FY25 revenue.

5x30 Path to growth and value creation
The company intends to achieve the following five objectives by 2030 ("5x30"):
<ul>
<li>Patients: More than three million patients treated per year</li>
<li>Product revenue: Double-digit compounded annual growth rate</li>
<li>Profitability: Five percentage point gross margin improvement over 2024</li>
<li>Pipeline: Clinical pipeline expansion with five novel programs in development</li>
<li>Partnerships: Establishing five partnerships including pipeline and commercial agreements</li>
</ul>

Guidance

Pacira Reports Prelim. 2024 Revenue Of $710M vs $675.0M YoY; Co. Sets 2030 Goals Including More Than 3M Patients Treated Yearly

On Tuesday, Pacira BioSciences, Inc.&nbsp; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) received FDA clearance to market a new Smart Tip designed to access the medial branch nerves to manage chronic <a target="_blank" href="https://www.benzinga.com//node/42841844" rel="noreferrer noopener">low back pain</a>.
The ioveraº system is a drug-free treatment that relieves pain via cryoneurolysis—a process whereby focused cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals.
Pain relief is typically experienced immediately after treatment, lasting for months as the nerve regenerates.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40321378/pain-management-focused-pacira-biosciences-loses-patent-fight-for-key-drug-jp-morga" rel="noreferrer noopener">Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path</a>
To date, the ioveraº portfolio has consisted of either a three-pronged Smart Tip featuring 8.5-mm long 27-gauge needles to treat superficial nerves or a single, 90-mm long, 20-guage Smart Tip ideally suited to treat deeper nerves.
It is most commonly used to treat knee pain but frequently used to manage pain in the hip, shoulder, chest, foot &amp; ankle, and more.
This new, 25-gauge 180-mm Smart Tip will allow for the treatment of deeper nerves, such as the medial branch nerve. It is specifically designed to relieve chronic low back pain associated with facet-mediated pain.
This longer-needle Smart Tip is designed for use through a cannula or introducer, allowing ice ball formation at deeper peripheral nerves.
Annually, 28 to 30 million Americans seek treatment for chronic back pain, yet only 2 to 3 million undergo interventional procedures.
With the introduction of this new iovera° Smart Tip, Pacira aims to address these gaps and elevate the standard of care.
The company adds that the product offers an alternative to conventional treatments, such as radiofrequency ablation, with substantial limitations.
A single-center randomized pilot study of the iovera° system showed:
<ul>
<li>Patients treated with iovera° reported pain scores more than 2 points lower at 180 and 360 days than those treated with RFA on the 0-10 NRS Pain scale.</li>
<li>At 360 days, patients in the iovera° group showed statistically and clinically significant improvements in functional outcomes, as evidenced by average Oswestry Disability Index (ODI) scores improving from moderate to minimal disability.</li>
<li>More iovera° patients expressed satisfaction with their pain management compared to those receiving RFA.</li>
<li>No serious adverse events were observed over the course of the study.</li>
</ul>
Price Action: PCRX stock is up 1.50% at $18.91 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42846580/rpm-international-q2-strong-sales-adjusted-ebit-growth-and-updated-fy25-guidance" target="_blank" rel="noreferrer noopener">Paint &amp; Coating Company RPM Beats Q2 Expectations But Signals Flat Q3; Stock Dips</a></li>
</ul>

Health Care

General

Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain

Pacira Biosciences shares are trading higher after the company announced it received FDA 510k clearance to market its new iovera° SmartTIp for chronic lower back pain via a medial branch nerve block.

Pacira BioSciences Receives FDA 510k Clearance To Market New iovera° SmartTip For Chronic Low Back Pain via Medial Branch Nerve Block

Across the recent three months, 6 analysts have shared their insights on Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $21.17, a high estimate of $39.00, and a low estimate of $15.00. Highlighting a 2.31% decrease, the current average has fallen from the previous average price target of $21.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1733313644_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Pacira BioSciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacira BioSciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pacira BioSciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Pacira BioSciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Pacira BioSciences</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Key Indicators: Pacira BioSciences's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Pacira BioSciences showcased positive performance, achieving a revenue growth rate of 2.83% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacira BioSciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -85.11%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Pacira BioSciences's ROE excels beyond industry benchmarks, reaching -17.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Pacira BioSciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -9.06%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Decoding 6 Analyst Evaluations For Pacira BioSciences

HC Wainwright &amp; Co. analyst Oren Livnat reiterates Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and maintains $39 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $39 Price Target

Biotech

Pacira Biosciences Received U.S. Patent No. 12,156,940 From The U.S. Patent And Trademark Office, Which Protects The Chemical Composition Of Exparel (Bupivacaine Liposome Injectable Suspension). The Company Expects The '940 Patent To Provide Protection Into July 2044

Pacira Secures New U.S. Patent For EXPAREL Composition, Expanding IP Protection Through 2044

Pacira Reports 104-Week Safety And Efficacy Data Following Local Administration Of PCRX-201 For Moderate To Severe Osteoarthritis Of Knee

Barclays analyst Balaji Prasad maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Equal-Weight and lowers the price target from $25 to $17.

Barclays Maintains Equal-Weight on Pacira BioSciences, Lowers Price Target to $17

Needham analyst Serge Belanger reiterates Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and maintains $22 price target.

Needham Reiterates Buy on Pacira BioSciences, Maintains $22 Price Target

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.75, a high estimate of $39.00, and a low estimate of $8.00. This current average has decreased by 44.53% from the previous average price target of $32.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731009644_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Pacira BioSciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$14.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Hardik Parikh</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacira BioSciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Pacira BioSciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Pacira BioSciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Pacira BioSciences: A Closer Look</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Pacira BioSciences: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Pacira BioSciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.05% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacira BioSciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.13%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Pacira BioSciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.17% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average at 0.74, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Pacira BioSciences: Insights From 8 Financial Analysts

RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Sector Perform and raises the price target from $15 to $16.

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $16

2024 Financial Guidance
Today the company is reiterating its full-year 2024 financial guidance as follows:
<ul>
<li>Total revenue of $680 million to $705 million;</li>
<li>Non-GAAP gross margin of 74% to 76%;</li>
<li>Non-GAAP R&amp;D expense of $70 million to $80 million;</li>
<li>Non-GAAP SG&amp;A expense of $245 million to $265 million; and</li>
<li>Stock-based compensation of $50 million to $55 million.</li>
</ul>

Pacira BioSciences Sees FY24 Revenue $680M-$705M Vs $692.7M Estimate

Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.70 by 18.57 percent. The company reported quarterly sales of $168.600 million which missed the analyst consensus estimate of $169.672 million by 0.63 percent. This is a 2.85 percent increase over sales of $163.926 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Pacira BioSciences Q3 2024 Adj. EPS $0.83 Beats $0.70 Estimate, Sales $168.600M Miss $169.672M Estimate

Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Pacira BioSciences will report an earnings per share (EPS) of $0.70.
Anticipation surrounds Pacira BioSciences's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.19, which was followed by a 5.68% increase in the share price the next day.
Here's a look at Pacira BioSciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.62</td>
<td>0.88</td>
<td>0.79</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.89</td>
<td>0.62</td>
<td>0.89</td>
<td>0.72</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>12.0%</td>
<td>-3.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730818942_0.png" alt="eps graph" />
<h3>Tracking Pacira BioSciences's Stock Performance</h3>
Shares of Pacira BioSciences were trading at $16.45 as of November 04. Over the last 52-week period, shares are down 45.22%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Observations about Pacira BioSciences</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Pacira BioSciences.
Analysts have given Pacira BioSciences a total of 7 ratings, with the consensus rating being Buy. The average one-year price target is $18.0, indicating a potential 9.42% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of EyePoint Pharmaceuticals, Liquidia and Phibro Animal Health, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for EyePoint Pharmaceuticals, with an average 1-year price target of $24.0, indicating a potential 45.9% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Liquidia, with an average 1-year price target of $26.08, implying a potential 58.54% upside.</li>
<li>Phibro Animal Health received a Neutral consensus from analysts, with an average 1-year price target of $18.5, implying a potential 12.46% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for EyePoint Pharmaceuticals, Liquidia and Phibro Animal Health, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pacira BioSciences</td>
<td>Buy</td>
<td>5.05%</td>
<td>$133.76M</td>
<td>2.13%</td>
</tr>
<tr>
<td>EyePoint Pharmaceuticals</td>
<td>Buy</td>
<td>4.09%</td>
<td>$8.08M</td>
<td>-12.89%</td>
</tr>
<tr>
<td>Liquidia</td>
<td>Buy</td>
<td>-23.55%</td>
<td>$2.17M</td>
<td>-37.51%</td>
</tr>
<tr>
<td>Phibro Animal Health</td>
<td>Neutral</td>
<td>7.10%</td>
<td>$87.15M</td>
<td>0.29%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Pacira BioSciences ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.
<h3>All You Need to Know About Pacira BioSciences</h3>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Financial Insights: Pacira BioSciences</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Pacira BioSciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.05% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Pacira BioSciences's net margin is impressive, surpassing industry averages. With a net margin of 10.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Pacira BioSciences's ROE stands out, surpassing industry averages. With an impressive ROE of 2.13%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Pacira BioSciences's ROA excels beyond industry benchmarks, reaching 1.17%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.74.
<a href="https://www.benzinga.com/quote/PCRX/earnings">To track all earnings releases for Pacira BioSciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Pacira BioSciences's Upcoming Earnings

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the appointment of Shawn Cross as Chief Financial Officer. In this role, Mr. Cross will be responsible for overseeing all aspects of the company's financial operations.

Management

Pacira BioSciences Appoints Shawn Cross As Chief Financial Officer

RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Sector Perform and raises the price target from $14 to $15.

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $15

Pacira (PCRX) BioSciences announced the receipt of U.S. Patent No. 12,156,940 from the U.S. Patent and Trademark Office, the U.S. PTO. The ‘940 pat...

Pacira awarded new U.S. patent covering EXPAREL composition

Columbia Convertible Securities Fund Q3 2024 Commentary

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacira Pharmaceuticals (PCRX – Research Report), A...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Amneal Pharmaceuticals (AMRX) and NextCure (NXTC)

Pacira (PCRX) BioSciences announced the granting of inducement awards on December 3, 2024 to four new employees under Pacira's Amended and Restated...

Pacira reports inducement grants under Nasdaq listing rule

DOMA Perpetual Capital Management, which beneficially owns approximately 4.14% of the outstanding shares of common stock of Pacira (PCRX) BioScienc...

DOMA Perpetual Capital to nominate four candidates to Pacira's board

Impax Small Cap Fund Q3 2024 Commentary

Carillon Scout Small Cap Fund Q3 2024 Commentary

Pacira (PCRX) BioSciences has received clearance from the U.S. Food & Drug Administration to market a new Smart Tip designed to access the medial b...

Pacira receives 510k clearance for iovera Smart Tip

Pacira BioSciences receives FDA 510k clearance for new iovera SmartTip

Full-year EXPAREL net product sales of $549.0 million in 2024, compared with $538.1 million in 2023. Full-year net product sales were comprised of ...

Pacira sees FY24 revenue $701M, consensus $695.18M

ABBV

AGEN

AMRX

BABA

BABAF

BKNG

BMYMP

DELL

DXCM

EXAS

GNRC

GTLS

HCAT

HERC

ICUI

INSP

LGND

LGNDZ

LGNXZ

LGNYZ

LGNZZ

MODG

NBIX

NEEXU

NXTC

PATK

PLUS

RKLB

TCOM

TGLS

TRPCF

TTGT

UCTT

VCTR

Press Releases

Pacira BioSciences Reports Third Quarter 2024 Financial Results

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Legal

Pacira Awarded New U.S. Patent Covering EXPAREL Composition

Financing

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.

VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO

Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization

BIVN

Liquidia

Merck & Co

Nuvation Bio

Novo Nordisk

Novartis

Ocular Therapeutix

Organon

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Pliant Therapeutics

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Septerna

Sanofi

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Pacira BioSciences

ニュース

最新ニュース Pacira BioSciences (NASDAQ:PCRX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル